Pricing Log in Create free account

GRI Bio, Inc. (GRI) vs Liminatus Pharma Inc. (LIMN)

GRI Bio, Inc. and Liminatus Pharma Inc. are both Biotechnology companies. GRI Bio, Inc. and Liminatus Pharma Inc. are of similar size ($3.5M and $3.4M). Across the 9 metrics below, GRI Bio, Inc. leads on 5 and Liminatus Pharma Inc. on 4.

Valuation

Metric GRI LIMN Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.32 8.05 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.77 n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (2,802.73%) (940.00%) (32.88%)
Free cash flow yield (313.92%) (164.16%) (23.13%)

Profitability

Metric GRI LIMN Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (142.02%) 294.43% (51.96%)
Return on assets (113.27%) (471.47%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GRI LIMN Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 92.12% (112.19%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GRI LIMN Biotechnology median
Debt to equity 0.00 4.80 0.00
Current ratio 10.30 1.12 4.97
Net debt to EBITDA 0.69 (0.37) 1.01

Dividend

Metric GRI LIMN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GRI LIMN Biotechnology median
Market cap 3.39m 3.53m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack